Search

BI increases commitments to sustainable development

At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development

Boehringer Ingelheim acquires Global Stem cell Technology

Boehringer Ingelheim acquires Global Stem cell Technology, Belgian veterinary biotech company, to strengthen its stem cell capabilities in Animal Health

Boehringer Ingelheim - Life Forward

Learn how we change life for the better for people and animals.

Boehringer Ingelheim acquires a stake in SoundTalks

Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme

Boehringer Ingelheim and Fraunhofer partnership

Boehringer Ingelheim and Fraunhofer IME launch collaboration which aims to develop sustainable animal health products

"To join Boehringer Ingelheim was the best ever decision"

Pharmacologist Michael Mark worked for us for 34 years. He played a key role in the research and development of several medications. Watch our video and discover our job opportunities.

1948-1990: Going global

The Boehringer Ingelheim history from 1948-1990, with milestones

commitments to sustainable development

On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities

Boehringer Ingelheim becomes member of IPC

Boehringer Ingelheim becomes member of IPC Boehringer Ingelheim is proud to join the International Poultry Council thus reaffirming its strong long-term commitment to shaping the future of poultry health. The International Poultry Council represents a uni

environmental sustainability commitments

On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability

EURORDIS Award

EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020

Boehringer Ingelheim Venture Fund invests precision antimicrobials

Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials

Groundbreaking oncology research zongertinib

Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio

Boehringer Ingelheim announces 2018 BVDzero Case Awards

Boehringer Ingelheim announces 2018 BVDzero Case Awards Boehringer Ingelheim will provide a total prize of €15,000 for the top 10 clinical cases entered Applications can be submitted on www.bvdzero.com

Positive results Diabetic Macular Ischemia treatment

HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment

Boehringer Ingelheim announces collaboration with MabGenesis

Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine

Boehringer Ingelheim and GST prepared bring innovation to equine market

Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine market

Boehringer founding sponsor of CKM Health Initiative

Boehringer Ingelheim founding sponsor of AHA's Cardiovascular-Kidney-Metabolic Health Initiative

Partnership Boehringer Ingelheim Lifebit health data

Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data

FDA Grants Breakthrough Status to Schizophrenia Treatment

Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic